Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

TSX:OPS - Post Discussion

Opsens Inc > About the CC and comments from analysts
View:
Post by bossu on Jul 18, 2022 9:35am

About the CC and comments from analysts

in summary a Great Conference

Conference Call Participants                 Comments

Rahul Sarugaser - Raymond James Ltd.  Very well done Congrats

Douglas Miehm - RBC Capital Markets     Excellent 

Scott McAuley - Paradigm Capital             Congrats

Nicholas Cortellucci - MPartners             Great to hear

Jeffrey Schacter - TD Wealth Private Investment Advice Congrats

So evry analysts are 'ultra positive'' on Opsen going forward
and the taget price revenues in the coming couple of years is stunning.
From Louis .
''' For fiscal year 2025, the vision on a consolidated basis is to achieve $100 million in sales. What would be the split between the OptoWire and the SavvyWire and the OEM business and the industrial business, we probably don't need to grow at that level at current time. But what I can say is that we think once we will be at $100 million in sales gross margin, percentage will increase. And at that time, we'll be in a great position from a cash flow standpoint

So far this year ( 9months) $ 28 271 M + $ 10 M = $ 38 M Aug (30 2022)
So a 2 to 3 years horizon to more that 2.5 time  the revenues .

In my ming a very bullish view of Opsens from his CEO.
Analysts  are buying the storey and so do I !
AT he current targets target price  from these firms are $3.35 (Stifel), $4.00 (RBC and MPartners), $4.10 (Paradigm) and $6.00 (Raymond James). 

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities